Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Editas Medicine, Inc. (EDIT)

7.25   0.22 (3.13%) 03-31 16:00
Open: 7.1 Pre. Close: 7.03
High: 7.37 Low: 7.05
Volume: 1,588,425 Market Cap: 500(M)

Technical analysis

as of: 2023-03-31 4:18:15 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 9.82     One year: 10.85
Support: Support1: 7    Support2: 5.82
Resistance: Resistance1: 8.41    Resistance2: 9.28
Pivot: 7.78
Moving Average: MA(5): 7.25     MA(20): 7.94
MA(100): 9.4     MA(250): 12.1
MACD: MACD(12,26): -0.6     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 12.5     %D(3): 11.6
RSI: RSI(14): 36.7
52-week: High: 20.04  Low: 7
Average Vol(K): 3-Month: 1,722 (K)  10-Days: 1,501 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ EDIT ] has closed above bottom band by 25.0%. Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.53 - 7.57 7.57 - 7.6
Low: 6.9 - 6.94 6.94 - 6.98
Close: 6.95 - 7.02 7.02 - 7.09

Company Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Headline News

Fri, 24 Mar 2023
Why Is Editas (EDIT) Down 21% Since Last Earnings Report? - Nasdaq

Tue, 14 Mar 2023
An investment is made in Editas Medical, Inc. by Twinbeech Capital ... - Best Stocks

Mon, 13 Mar 2023
Twinbeech Capital LP Takes Position in Editas Medicine, Inc ... - MarketBeat

Mon, 13 Mar 2023
A few Editas Medicine, Inc. (NASDAQ:EDIT) insiders sold shares in the last 12 months: Not a good sign for shareholders - Simply Wall St

Sat, 11 Mar 2023
Editas Medicine, Inc. receives a $271,000 investment from Verition ... - Best Stocks

Thu, 09 Mar 2023
26796 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 69 (M)
% Held by Insiders 6.719e+007 (%)
% Held by Institutions 0.4 (%)
Shares Short 20,940 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.1961e+008
EPS Est Next Qtl -0.77
EPS Est This Year -2.89
EPS Est Next Year -2.85
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 146.2
Return on Equity (ttm) -23.8
Qtrly Rev. Growth 1.971e+007
Gross Profit (p.s.) -25.06
Sales Per Share -25.38
EBITDA (p.s.) -8.17105e+007
Qtrly Earnings Growth -3.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -177 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -1.7
Price to Book value 0
Price to Sales -0.29
Price to Cash Flow 2.56

Stock Dividends

Dividend 0
Forward Dividend 1.916e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.